HBW Insight catches up with our own US Executive Editor, Malcolm Spicer, to find out all about Perrigo subsidiary HRA Pharma’s Rx-to-OTC switch of its daily contraceptive, Opill. Currently under consideration by the US Food and Drug Administration after a positive recommendation from its advisory committees, Spicer draws on 30+ years of writing about the US consumer healthcare market, as well as his extensive coverage of the subject, to tell us all we need to know about this historic switch.

What You Need To Know About HRA/Perrigo’s Historic US OTC Pill Switch With HBW’s Malcolm Spicer

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

New tracks tagged #Perrigo,